Vflow21

Company Overview

Snapshot

Founded in July 2021 by Anat Horev and Bilha Cahana, Vflow21 operates with 1–10 employees. The company has secured funding across two rounds from two investors, with Sanara Capital leading a round in April 2025.

Business overview

Vflow21 is a medical device company specializing in innovative solutions for neurovascular diseases. The company's core focus is on developing treatments for conditions such as Idiopathic Intracranial Hypertension and Tinnitus. Operating within the Health Tech & Life Sciences sector, Vflow21 serves the healthcare industry by providing advanced medical devices and therapeutics.

Company Intelligence Q&A

What is Vflow21's primary focus?

Vflow21 is a medical device company focused on developing innovative solutions for neurovascular diseases, specifically targeting Idiopathic Intracranial Hypertension and Tinnitus Treatment.

When was Vflow21 founded and by whom?

Vflow21 was founded in July 2021 by co-CEOs Anat Horev and Bilha Cahana.

Which investors have participated in Vflow21's funding rounds?

Vflow21 has received funding from investors including Sanara Capital and the Israel Innovation Authority.